Reported 8 days ago
Source: WSJ
Reported 8 days ago
Source: BARRONS
Reported 8 days ago
Source: INVESTORS
Reported 8 days ago
As Denmark's Novo Nordisk looks to replace CEO Lars Fruergaard Jorgensen, analysts suggest the company should seek a leader from the U.S., its largest market. With Novo facing increased competition from U.S. rival Eli Lilly in the obesity drug sector, particularly with disparities in sales of their respective medications, having a CEO familiar with the U.S. pharmaceutical landscape could be advantageous. Historically, Novo has had only Danish CEOs, marking a potential shift in company strategy if they choose to appoint an external candidate.
Source: YAHOO
Reported 8 days ago
Source: YAHOO
Reported 8 days ago
On May 14, Jim Cramer discussed Bristol-Myers Squibb (NYSE:BMY), emphasizing its struggles due to an impending patent cliff affecting lucrative drugs. While he noted the company's decent oncology portfolio and a 5.6% dividend yield, he advised caution in buying more stock until they see improvements in its new drug COBENFY, which recently had disappointing study results. Cramer is holding off on additional purchases, expecting the stock may drop further.
Source: YAHOO
Reported 8 days ago
In a recent episode of Mad Money, Jim Cramer praised AbbVie Inc. (NYSE:ABBV) as one of his top picks, emphasizing its strong franchises in various medical fields and lack of impending patent cliffs. Despite a recent drop in stock price due to market conditions, he believes AbbVie represents a relatively safe investment, though he suggests evaluating other potential high-return AI stocks.
Source: YAHOO
Reported 8 days ago
Jim Cramer points out that investors are avoiding Johnson & Johnson due to ongoing legal issues linked to past talcum powder claims, despite the company's strong financial position and product pipeline. He emphasizes that the current yield does not sufficiently compensate for the associated risks, leading to a general retreat from the stock.
Source: YAHOO
Reported 8 days ago
Jim Cramer labeled Procter & Gamble (PG) a 'dividend aristocrat' but expressed concerns about its yield not sufficiently compensating for risk. Despite PG's strong consumer product lineup and a long history of increasing dividends, he suggested that promising AI stocks could offer better returns with less risk.
Source: YAHOO
Reported 8 days ago
In a recent episode of Mad Money, Jim Cramer expressed concerns about Colgate-Palmolive's stock, suggesting it 'could go lower.' He pointed out the company's strong product portfolio but noted its significant price drop from highs and lackluster yield. Cramer believes investors might find better opportunities in AI stocks with higher growth potential.
Source: YAHOO
Reported 8 days ago
Source: INVESTORS
Reported 8 days ago
In a recent discussion, Jim Cramer praised PepsiCo, calling it an exceptional company with a strong portfolio that includes globally recognized brands. Despite its current stock price being significantly lower than its peak, Cramer believes it's worth much more than its market value. He expressed concerns about potential regulations affecting its snack business but remains optimistic about the company's future, emphasizing that its performance could rebound.
Source: YAHOO
Reported 8 days ago
In this episode of 'Wealth with Brad Smith,' estate planning expert Jere Doyle discusses tax-efficient strategies for passing down a home, which is often a significant asset. He outlines three main methods: gifting the home while alive, selling it to children, or having them inherit it after death. Gifting can lead to tax implications due to capital gains, while inheriting allows for a stepped-up basis, making it the most tax-efficient option. Doyle highlights the potential complexities of each method, pointing out that simplicity often works best in estate planning.
Source: YAHOO
Reported 8 days ago
Source: BARRONS
Reported 8 days ago
Source: INVESTORS
Reported 8 days ago
Source: BARRONS
Reported 8 days ago
Intel's new chip manufacturing technology, named 18A, represents both a vital opportunity and significant risk for the company as it aims to reclaim its status in the semiconductor industry from TSMC. This process, featuring advanced techniques like gate-all-around transistors and backside power, is intended to enhance chip performance and attract outside clients. However, Intel faces challenges in meeting ambitious goals, recovering from past financial losses, and competing against established players like TSMC, which have already adopted similar technologies. The success of 18A is crucial for Intel's future, with outcomes expected later this year.
Source: YAHOO
Reported 8 days ago
Source: BARRONS
Reported 8 days ago
Source: WSJ
Reported 8 days ago
Source: INVESTORS